Determining the Repertoire of IGH Gene Rearrangements to Develop Molecular Markers for Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia

被引:7
|
作者
Brisco, Michael J. [1 ,2 ]
Latham, Sue [1 ,2 ]
Sutton, Rosemary [3 ]
Hughes, Elizabeth [1 ,2 ]
Wilczek, Vicki [1 ,2 ]
van Zanten, Katrina [1 ,2 ]
Budgen, Bradley [1 ,2 ]
Bahar, Anita Y. [3 ]
Malec, Maria [3 ]
Sykes, Pamela J. [1 ,2 ]
Kuss, Bryone J. [1 ,2 ]
Waters, Keith
Venn, Nicola C. [3 ]
Giles, Jodie E. [3 ]
Haber, Michelle [3 ]
Norris, Murray D. [3 ]
Marshall, Glenn M. [4 ]
Morley, Alexander A. [1 ,2 ]
机构
[1] Flinders Univ S Australia, Dept Hematol & Genet Pathol, Adelaide, SA, Australia
[2] Med Ctr, Adelaide, SA, Australia
[3] Univ New S Wales, Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia
[4] Sydney Childrens Hosp, Ctr Childrens Canc & Blood Disorders, Sydney, NSW, Australia
来源
JOURNAL OF MOLECULAR DIAGNOSTICS | 2009年 / 11卷 / 03期
基金
英国医学研究理事会;
关键词
TIME QUANTITATIVE PCR; CLONAL IMMUNOGLOBULIN; CONCERTED ACTION; HEAVY-CHAIN; CHILDHOOD; RELAPSE; CHILDREN; QUANTIFICATION; INDUCTION; PROTOCOLS;
D O I
10.2353/jmoldx.2009.080047
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia were identified by determining, at the time of diagnosis, the repertoire of rearrangements of the immunoglobulin heavy chain (IGH) gene using segment-specific variable (V), diversity (D), and junctional (J) primers in two different studies that involved a total study population of 75 children and 18 adults. This strategy, termed repertoire analysis, was compared with the conventional strategy of identifying markers using family-specific V, D, and J primers for a variety of antigen receptor genes. Repertoire analysis detected significantly more markers for the major leukemic clone than did the conventional strategy, and one or more IgH rearrangements that were suitable for monitoring the major clone were detected in 96% of children and 94% of adults. Repertoire analysis also detected significantly more IGH markers for minor clones. Some minor clones were quite large and a proportion of them would not be able to be detected by a minimal residual disease test directed to the marker for the major clone. IGH repertoire analysis at diagnosis has potential advantages for the identification of molecular markers for the quantification of minimal residual disease in acute lymphoblastic leukemia cases. An IGH marker enables very sensitive quantification of the major leukemic clone, and the detection of minor clones may enable early identification of additional patients who are prone to relapse. (J mol Diagn 2009, 11:194-200; DOI: 10.2353/jmoldx.2009.080047)
引用
收藏
页码:194 / 200
页数:7
相关论文
共 50 条
  • [21] The repertoire of gene rearrangements in acute lymphoblastic leukemia.
    Morley, AA
    Brisco, MJ
    Sykes, PJ
    Latham, S
    Hughes, E
    Wilczek, V
    Kuss, BJ
    Waters, K
    BLOOD, 2005, 106 (11) : 422A - 423A
  • [22] Prognostic-significance of minimal residual disease after intensive induction therapy in childhood B-lineage acute lymphoblastic leukemia.
    Gruhn, B
    Hongeng, S
    Yi, H
    Hancock, ML
    Rubnitz, JE
    Neale, GAM
    Kitchingman, GR
    BLOOD, 1997, 90 (10) : 1877 - 1877
  • [23] Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
    Maury, Sebastien
    Chevret, Sylvie
    Thomas, Xavier
    Heim, Dominik
    Leguay, Thibaut
    Huguet, Francoise
    Chevallier, Patrice
    Hunault, Mathilde
    Boissel, Nicolas
    Escoffre-Barbe, Martine
    Hess, Urs
    Vey, Norbert
    Pignon, Jean-Michel
    Braun, Thorsten
    Marolleau, Jean-Pierre
    Cahn, Jean-Yves
    Chalandon, Yves
    Lheritier, Veronique
    Beldjord, Kheira
    Bene, Marie C.
    Ifrah, Norbert
    Dombret, Herve
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (11): : 1044 - 1053
  • [24] Cutaneous involvement with B-lineage acute lymphoblastic leukemia
    Nabhan, Chadi
    Tolentino, Angelica
    Meyer, Andrew
    Tallman, Martin S.
    LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 987 - 989
  • [25] Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody
    Seidel, Ursula Joerdis Eva
    Schlegel, Patrick
    Grosse-Hovest, Ludger
    Hofmann, Martin
    Aulwurm, Steffen
    Pyz, Elwira
    Schuster, Friedhelm R.
    Meisel, Roland
    Ebinger, Martin
    Feuchtinger, Tobias
    Teltschik, Heiko-Manuel
    Witte, Kai-Erik
    Schwarze, Carl-Philipp
    Rammensee, Hans-Georg
    Handgretinger, Rupert
    Jung, Gundram
    Lang, Peter
    MOLECULAR THERAPY, 2016, 24 (09) : 1634 - 1643
  • [26] MOLECULAR MECHANISMS OF CLONAL EVOLUTION IN B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA
    CHOI, Y
    DU, TL
    WARD, P
    OVERTURF, P
    BRECHER, M
    BALLOW, M
    GREENBERG, SJ
    CLINICAL RESEARCH, 1994, 42 (02): : A125 - A125
  • [27] Minimal Residual Disease Detection and Evolved IGH Clones Analysis in Acute B Lymphoblastic Leukemia Using IGH Deep Sequencing
    Wu, Jinghua
    Jia, Shan
    Wang, Changxi
    Zhang, Wei
    Liu, Sixi
    Zeng, Xiaojing
    Mai, Huirong
    Yuan, Xiuli
    Du, Yuanping
    Wang, Xiaodong
    Hong, Xueyu
    Li, Xuemei
    Wen, Feiqiu
    Xu, Xun
    Pan, Jianhua
    Li, Changgang
    Liu, Xiao
    FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [28] Frequencies of TCR gamma,delta and IGH gene rearrangements in acute lymphoblastic leukemias and implications in quantitation of minimal residual disease
    Nancy, Nirmala
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 440 - 441
  • [29] Combined analysis of minimal residual disease at two time points and its value for risk stratification in childhood B-lineage acute lymphoblastic leukemia
    Cui, Lei
    Li, Zhigang
    Wu, Minyuan
    Li, Weijing
    Gao, Chao
    Deng, Guoren
    LEUKEMIA RESEARCH, 2010, 34 (10) : 1314 - 1319
  • [30] KINETICS OF MINIMAL RESIDUAL DISEASE DURING INDUCTION CONSOLIDATION THERAPY IN STANDARD-RISK ADULT B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA
    SCHOLTEN, C
    FODINGER, M
    MITTERBAUER, M
    LACZIKA, K
    MITTERBAUER, G
    HAAS, OA
    KNOBL, P
    SCHWARZINGER, I
    THALHAMMER, R
    PURTSCHER, B
    GEISSLER, K
    MANNHALTER, C
    LECHNER, K
    JAEGER, U
    ANNALS OF HEMATOLOGY, 1995, 71 (04) : 155 - 160